• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

by Annie De Groot | Jun 30, 2020

2020 TCWP
Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

by Annie De Groot | Sep 9, 2019

EpiVax_PANDA_Taspoglutide_April_19_Final
Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics

Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics

by Sarah Moniz | Aug 15, 2018

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

by Sarah Moniz | Aug 15, 2018

Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

by Sarah Moniz | Apr 10, 2018

« Older Entries
Next Entries »

Recent Posts

  • The Tregs as Medicine Symposium | Advances in Tolerance Research
  • Optimize Your Immunogenicity Strategy with Trusted Expert Advice 
  • Tregs, Epitopes, and the Future of Immune Tolerance
  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.